Clinical Performance
Sensitivity and specificity against a comparator or clinical reference method, generated in the population the device is intended for.
510(k) studies
510(k) Clinical Studies, Run by a Diagnostics-Only Team.
A 510(k) submission stands or falls on whether the performance data supports substantial equivalence. We design and run the studies that produce that data, using sites already qualified to handle IVD protocols.
The evidence
Substantial Equivalence, Demonstrated.
A 510(k) argues that your device performs equivalently to a legally marketed predicate. For an in vitro diagnostic, that argument is built from performance data, and the four pillars below are where studies most often succeed or stall.
Analytical Performance
Precision, reproducibility, detection limits, linearity, interference, and cross-reactivity, typically following CLSI-style designs.
Reproducibility
Consistent results across sites, operators, days, and lots. Commonly structured across three or more sites to show the device travels.
Intended Use Population
Prospectively collected specimens from real patients presenting with the relevant signs and symptoms, not banked convenience samples alone.
Where timelines actually go
The Study Isn't Slow. Site Startup Is.
Most 510(k) programs do not lose months to enrollment. They lose them before enrollment starts, qualifying sites that have never run an IVD protocol, negotiating budgets and contracts one at a time, and waiting on IRB submissions that could have been anticipated.
Studybox maintains a network of over 100 pre-qualified sites across point-of-care, urgent care, and home-use settings, already contracted and already familiar with diagnostic protocols. Because qualification happened before your study existed, activation typically takes about four weeks instead of the three to six months a cold site network requires.
- Sites matched to your intended use profile, not just availability.
- Geographic and demographic diversity to satisfy FDA expectations.
- No study-specific qualification visits before you can start.
- One sponsor contract covering both CRO services and site access.
How we run it
Predicate to Clearance.
One team, one point of contact, no handoffs between a CRO and a separate site organization.
-
Predicate and Pathway Review
We confirm the predicate strategy and the evidence FDA will expect before a protocol is written, so the study is designed against the actual submission.
-
Protocol Design
Endpoints, comparator method, sample size, and enrollment criteria built to support a substantial equivalence argument.
-
Site Matching
Sites selected against the intended use profile and geographic diversity requirements, drawn from a pre-qualified network.
-
Enrollment and Execution
Supply management, coordinator support, and site oversight run under one team with a single point of contact.
-
Monitoring and Data
Live data review, QA, and deviation management, so problems surface during the study rather than at lock.
-
Submission Support
Statistical analysis, clinical study report, and support responding to FDA questions through to clearance.
FAQ
510(k) Questions We Get Often.
01 Does every IVD 510(k) need a clinical study?
No. The evidence FDA expects depends on the device, its predicate, and its intended use. Some submissions are supported largely by analytical data, while others require prospective clinical performance data in the intended use population. The predicate and intended use should be settled before the study is designed.
02 How many sites does a 510(k) study need?
It depends on the device and the claims, but reproducibility work is commonly structured across three or more sites, and clinical performance studies often need multiple geographically diverse sites to capture a representative population. We match site count and location to the specific submission rather than applying a fixed template.
03 Can you use banked or retrospective specimens?
Sometimes, particularly for analytical work or rare conditions. Clinical performance claims usually need prospectively collected specimens from patients in the intended use population. We run both prospective study collection and standing specimen collection under a pre-approved IRB protocol.
04 How long does a 510(k) clinical study take?
Timelines depend on device complexity, enrollment requirements, and seasonality of the target condition. Because our sites are pre-qualified for IVD protocols, activation typically takes about four weeks rather than the three to six months a study-specific qualification cycle usually requires.
05 Do you support Dual Submission for 510(k) and CLIA Waiver together?
Yes. If the device is intended for waived settings, running a Dual Submission study is usually more efficient than clearing the 510(k) first and pursuing a waiver afterwards. See our Dual Submission page for how the combined design works.
Let's talk about your submission
Bring us the predicate. We'll bring the study.
Tell us about your device and intended use, and we'll come back with the study design and site plan within one business day.